NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
XFLS Xfuels Inc
WAFD Washington Federal Inc
CNIKF Canada Nickel Company Inc
VMW VMware Inc
FORM FormFactor Inc
GLNG Golar LNG Ltd
DH Definitive Healthcare Corp
PLMIU Plum Acquisition I Corp
TSLA Tesla Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
$4.06
Day's Change
-0.32 (-7.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.43
Day's Low
3.82
Volume
(Light)
Volume:
727,926

10-day average volume:
8,674,323
727,926

Display:

Providers:

UpdateCancel
6 providers
May 19, 2022
Thinking about buying stock in Neurometrix, Grab, SIGA Technologies, Inovio Pharmaceuticals, or Roblox?

InvestorsObserver issues critical PriceWatch Alerts for NURO, GRAB, SIGA, INO, and RBLX. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

NeuroMetrix Reports that Quell(R) Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

EQNX::TICKER_START (NASDAQ:NURO), EQNX::TICKER_END NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of...(Globe Newswire)

April 26, 2022
NeuroMetrix Reports Q1 2022 Financial Results

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population...(Globe Newswire)

April 19, 2022
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April 26...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.